KRAS and pancreatic ductal adenocarcinoma: <h4>Background/objectives</h4>Pancreatic ductal adenocarcinoma (PDAC) arises predominantly from activating KRAS mutations, yet individual genetic variants differ markedly in signaling output and clinical impact.